Aortic rupture following acute aortitis in a patient with head and neck carcinoma treated with nivolumab: a rare but severe immune-related adverse event-Reference-Cited by-同舟云学术

Aortic rupture following acute aortitis in a patient with head and neck carcinoma treated with nivolumab: a rare but severe immune-related adverse event

Published:2024-02-03 Issue:4 Volume:281 Page:2037-2040
ISSN:0937-4477
Container-title:European Archives of Oto-Rhino-Laryngology
language:en
Short-container-title:Eur Arch Otorhinolaryngol

Author:

Ohno Yuki,Ueki Yushi^ORCID,Oshima Shusuke,Omata Jo,Yokoyama Yusuke,Takahashi Takeshi,Shodo Ryusuke,Yamazaki Keisuke,Horii Arata

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00405-024-08495-2.pdf

Reference16 articles.

1. Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867. https://doi.org/10.1056/NEJMoa1602252

2. Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212):1915–1928. https://doi.org/10.1016/S0140-6736(19)32591-7

3. Ricciuti B, Genova C, De Giglio AD et al (2019) Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol 145(2):479–485. https://doi.org/10.1007/s00432-018-2805-3

4. Freeman-Keller M, Kim Y, Cronin H et al (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22(4):886–894. https://doi.org/10.1158/1078-0432.CCR-15-1136

5. Ishihara H, Takagi T, Kondo T et al (2019) Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. Urol Oncol 37(6):355.e21-355.e29. https://doi.org/10.1016/j.urolonc.2019.03.003

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nivolumab;Reactions Weekly;2024-04-13